BiondVax Pharmaceuticals (BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, announced today that its patent application in the United States, titled "Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines," has completed examination, and is allowed for issuance as a patent. The invention covers the use of BiondVax's universal flu vaccine as a prime-boost to the current commercially available flu vaccine.
A US-publicly listed, Israeli-based company, BiondVax is dedicated to the development of a universal flu vaccine. The company’s technology utilizes a unique, proprietary combination of conserved and common epitopes from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect. Results from BiondVax's completed clinical trials have shown significantly increased effectiveness against multiple flu strains.
"Current flu vaccines are strain specific and are not particularly effective against circulating 'wild-type' strains due to mismatches,” said Dr. Ron Babecoff, CEO of BiondVax. “In fact, last year's seasonal flu vaccine was only 23% effective. Conversely, our vaccine provides long-lasting and higher effectiveness against multiple flu strains."
Along with this significant milestone, the company has reported a number of recent operational highlights, including:
- Announcing that their patent application on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines was accepted in Israel.
- Receipt of patent approval in Korea.
- Successfully moving towards the company’s goal of reaching phase 3 trials in the 2017/2018.
- Holding patent protection in various countries, namely the United States, Europe, Japan, Hong Kong, Australia, China, Russia, and Mexico.
With the flu leaving millions around the world vulnerable, particularly children and the elderly, BiondVax progress and innovation has the potential to save countless lives. Another awarded patent for the company means bringing the world one step closer to a solution that actually works. "Our newly approved US patent demonstrates the novel nature of our vaccine technology,” said Babecoff, “and strengthens our IP portfolio for many years to come."
For more information about BiondVax, visit www.biondvax.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of
1933 and in the interest of full disclosure, we call the reader's
attention to the fact that Equities.com, Inc. may be compensated by the
companies profiled in the Spotlight Companies section. The purpose of
these profiles is to provide awareness of these companies to investors
in the micro, small-cap and growth equity community and should not in
any way come across as a recommendation to buy, sell or hold these
securities. Equities.com is not a registered broker, broker dealer,
investment advisor, analyst, investment banker or underwriter. All
profiles are based on information that is available to the public. The
information contained herein should not be considered to be
all-inclusive and is not guaranteed by Equities.com to be free from
misstatement or errors. Readers are reminded to do their own due
diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer